CD44和HIF1α的肿瘤表达可预测I期口腔鳞状细胞癌的预后。
Tumoral Expression of CD44 and HIF1α Predict Stage I Oral Cavity Squamous Cell Carcinoma Outcome.
作者信息
Dunkel Johannes, Vaittinen Samuli, Koivunen Petri, Laranne Jussi, Mäkinen Markus J, Tommola Satu, Irjala Heikki
机构信息
Medicity Research Laboratory and Turku Doctoral Programme of Molecular Medicine University of Turku.
the Department of Pathology University of Turku and Turku University Hospital Turku.
出版信息
Laryngoscope Investig Otolaryngol. 2016 Jan 14;1(1):6-12. doi: 10.1002/lio2.3. eCollection 2016 Feb.
OBJECTIVES/HYPOTHESIS: No biomarkers are used to estimate the prognosis in oral cavity squamous cell carcinoma (OSCC). In our previously published work, we have reported the prognostic value of CD44 and hypoxia inducible factor (HIF)-1α in patients with stage I disease.
STUDY DESIGN
In this study, we tested our previous observations in a larger cohort. We also studied the predictive value of common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 in this material.
METHODS
CD44, HIF1α, and CLEVER-1 were immunohistochemically analyzed in paraffin-embedded tissue material of stage I OSCC patients treated at three Finnish university hospitals. Microscopy results were correlated with OSCC outcome.
RESULTS
As in our pilot study, the CD44HIF1α signature was associated with poorer disease-free survival. Clear correlations between CLEVER-1 expression and clinical outcome were not evident.
CONCLUSION
Our results suggest that immunohistochemistry of CD44 and HIF1α may be useful in identification of patients with poor prognoses. These parameters could be used to select the optimal treatment modalities for stage I OSCC patients.
LEVEL OF EVIDENCE
2b.
目的/假设：目前尚无生物标志物可用于评估口腔鳞状细胞癌（OSCC）的预后。在我们之前发表的研究中，我们报道了CD44和缺氧诱导因子（HIF）-1α在I期疾病患者中的预后价值。
研究设计
在本研究中，我们在更大的队列中验证了我们之前的观察结果。我们还研究了共同淋巴内皮和血管内皮受体（CLEVER）-1在该样本中的预测价值。
方法
对在芬兰三家大学医院接受治疗的I期OSCC患者的石蜡包埋组织样本进行CD44、HIF1α和CLEVER-1的免疫组织化学分析。显微镜检查结果与OSCC的预后相关。
结果
与我们的初步研究一样，CD44HIF1α特征与较差的无病生存率相关。CLEVER-1表达与临床结果之间没有明显的相关性。
结论
我们的结果表明，CD44和HIF1α的免疫组织化学检测可能有助于识别预后不良的患者。这些参数可用于为I期OSCC患者选择最佳治疗方式。
证据等级
2b。
Zotero 插件